Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Scynexis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Scynexis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Scynexis Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Scynexis Raises Additional US$6 Million In Venture Financing 11
Partnerships 12
Scynexis Enters Into Co-Marketing Agreement With R-Pharm For SCY-078 12
Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 13
Licensing Agreements 14
Scynexis Enters into Licensing Agreement with Waterstone Pharma for SCY-635 14
Equity Offering 15
Scynexis Prices Public Offering of Shares and Warrants for USD30 Million 15
Scynexis Raises USD22.5 million in Public Offering of Shares and Warrants 17
Scynexis Raises USD41 Million in Public Offering of Shares 19
Scynexis Raises USD62 Million in IPO 21
Asset Transactions 23
Cypralis Acquires Cyclophilin Inhibitor Assets from Scynexis 23
Avista Pharma Acquires Contract Services Business from Scynexis 24
Accelrys Acquires Hit Explorer Operating System From Scynexis 26
Scynexis Inc – Key Competitors 27
Scynexis Inc – Key Employees 28
Scynexis Inc – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Aug 09, 2018: SCYNEXIS announces second quarter 2018 financial results 30
May 08, 2018: SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update 32
Mar 13, 2018: SCYNEXIS Reports Full Year 2017 Financial Results 34
Nov 07, 2017: SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update 36
Aug 08, 2017: SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update 38
May 08, 2017: SCYNEXIS Reports First Quarter 2017 Financial Results 40
May 08, 2017: SCYNEXIS Q1 net loss decreases 41
Mar 13, 2017: SCYNEXIS Reports Full Year 2016 Financial Results and Provides Company Update 42
Corporate Communications 44
Jan 26, 2017: SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors 44
Product News 45
10/05/2017: SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017 45
07/18/2018: The World Health Organization Recognizes New Antifungal Class by Granting “ibrexafungerp” to SCYNEXIS as the International Non-Proprietary Name for SCY-078 46
06/27/2018: SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting 47
06/15/2017: New Study Further Demonstrates In Vitro Activity of SCYNEXIS’ Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains 48
06/14/2018: SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018 49
06/11/2018: SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018 50
06/05/2017: Eight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Safety Profile of Lead Anti-Infective Candidate SCY-078 51
05/24/2018: SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018 52
04/21/2017: SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID 53
04/10/2018: SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease 54
Product Approvals 55
Mar 02, 2017: SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDAs request 55
Clinical Trials 56
Jul 10, 2018: SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis 56
Jun 06, 2018: SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology 58
May 01, 2018: SCYNEXIS’s Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC 59
Apr 23, 2018: SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis 60
Mar 20, 2018: SCYNEXIS Presents Data at Superbugs and Superdrugs 2018 61
Feb 01, 2018: SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018 62
Jan 04, 2018: SCYNEXIS Provides Corporate and SCY-078 Pipeline Update 63
Sep 27, 2017: SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017 65
Aug 14, 2017: SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting 66
Aug 03, 2017: SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis 67
May 24, 2017: Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS’ Lead Agent to Combat Serious and Life-threatening Fungal Infections 68
May 11, 2017: Potent in vitro Activity of SCYNEXIS SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention 70
May 08, 2017: SCYNEXIS Provides Update on IV Formulation Development Status 72
Apr 25, 2017: Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS’ Lead Anti-infective Candidate SCY-078 73
Apr 12, 2017: SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases 75
Feb 24, 2017: First Systematic Study of Deadly, Antibiotic-Resistant Fungus Reported 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78
Scynexis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Scynexis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Scynexis Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Scynexis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Scynexis Raises Additional US$6 Million In Venture Financing 11
Scynexis Enters Into Co-Marketing Agreement With R-Pharm For SCY-078 12
Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 13
Scynexis Enters into Licensing Agreement with Waterstone Pharma for SCY-635 14
Scynexis Prices Public Offering of Shares and Warrants for USD30 Million 15
Scynexis Raises USD22.5 million in Public Offering of Shares and Warrants 17
Scynexis Raises USD41 Million in Public Offering of Shares 19
Scynexis Raises USD62 Million in IPO 21
Cypralis Acquires Cyclophilin Inhibitor Assets from Scynexis 23
Avista Pharma Acquires Contract Services Business from Scynexis 24
Accelrys Acquires Hit Explorer Operating System From Scynexis 26
Scynexis Inc, Key Competitors 27
Scynexis Inc, Key Employees 28
List of Figures
Scynexis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Scynexis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9